| Trial | Treatments | Patients | Method |
|---|
| Almallah, 1998 | fish oil extract, 15 ml/d (5.6g EPA + DHA) (n=18) vs. placebo (sunflower oil, 15 ml/d) (n=18) | people with distal procto-collitis (ulcerative colitis) | single blind and outcome ass. Parallel groups Sample size: 18/18 Primary endpoint: FU duration: 6 months |
| Bemelmans, 2002 | a-lin rich margarine (80% fat of which 15% was a-lin) (n=51) vs. linoleic rich margarine (80% fat of which 0.3% was a-lin), identical in taste and packaging (n=52) | patients with multiple cardiovascular risk factors (10 yr IHD risk ~20%) | double-blind Parallel groups Sample size: 51/52 Primary endpoint: IHD risk FU duration: 24 months |
| Borchgrevink, 1966 | linseed oil 10 ml/d initially, later raised to 20 or 30 ml/d (4.5g/d a-lin, later 9 or 13.5 g/d) (n=100) vs. placebo (corn oil, 10 ml/d initially, later raised to 20 or 30 ml/d) (n=100) | men with impending or recent myocardial infarctionage/p | double-blind Parallel groups Sample size: 100/100 Primary endpoint: FU duration: mean 10 months (range 3-16 mo) |
| Brox, 2001 | seal oil - 15 ml/d (2.6g EPA + DHA) (n=40) vs. no supplement (n=40) | dyslipidaemia | open with blind assessment Sample size: 40/40 Primary endpoint: FU duration: |
| Dry, 1991 | Liparmonyl (1g/d EPA + DHA) (n=6) vs. placebo (n=6) | people with asthma | double blind Parallel groups Sample size: 6/6 Primary endpoint: FU duration: 12 months |
| Franzen, 1993 | fish oil capsules, 9g/d (1.8g EPA + 1.4g DHA daily) (n=15) vs. olive oil capsules (n=15) | people with angiographically determined CHDg | double-blind Parallel groups Sample size: 15/15 Primary endpoint: FU duration: 12 months |
| Geusens, 1994 | high and ow dose fish oil capsules (n=60) vs. placebo (olive oil capsules, 6/d) (n=30) | people with active rheumatoid arthritis on NSAIDs or DMARDs | double blind Parallel groups Sample size: 60/30 Primary endpoint: arthritic symptoms FU duration: 12 months |
| Katan, 1997 | Fish oil capsules, all took 9 per day (1.1g omega-3 fats low dose, 2.2g medium dose, 3.3g high dose per day) (n=44) vs. 9 olive and palm oil capsules (0g omega-3 fats per day)j (n=14) | healthy monks | NA Parallel groups Sample size: 44/14 Primary endpoint: tissue incorporation FU duration: 12 months |
| Leaf, 1994 | fish oil concentrate capsules 10x1 g/d (6.9g/d EPA + DHA) (n=275) vs. placebo (corn oil capsules 10x1 g/d with 0.4% fish oil to maintain blinding (0.003g/d EPA + DHA)) (n=276) | people undergoing angioplasty | double blind Parallel groups Sample size: 275/276 Primary endpoint: restenosis FU duration: 6 months |
| Loeschke, 1996 | fish oil capsules 6x1 g/d (5.1g/d omega-3 fats), with orange flavour (n=31) vs. placebo (maize oil capsules 6x1 g/d with orange flavour) (n=33) | people with ulcerative colitis, in remission | double-blind Parallel groups Sample size: 31/33 Primary endpoint: relapse-free time FU duration: 24 months |
| Lorenz-Meyer, 1996 | ethyl ester fish oil concentrate capsules 6x1 g daily (5.1g/d EPA + DHA) (n=70) vs. placebo (corn oil capsules 6x1 g daily) (n=65) | people with Crohn’s disease in remission | double blind Parallel groups Sample size: 70/65 Primary endpoint: relapse of Crohn’s diseaseilyitm FU duration: 12 months |
| Malaguarnera, 1999 | EPA + DHA daily (3g/d EPA + DHA) plus IFNa subcutaneously (n=26) vs. IFNa subcutaneously only (n=26) | chronic hepatitis with ALT =2x normal limit for =12 mo | open Parallel groups Sample size: 26/26 Primary endpoint: liver enzymesina FU duration: 6 months |
| Sacks (TOHP 1), 1994 | fish oil (n=-9) vs. placebo (n=-9) | double blind | double-blind Sample size: -9/-9 Primary endpoint: FU duration: |
| Shimizu, 1995 | EPA-ethyl capsules 3/d (0.9g/d EPA) (n=29) vs. no treatment (n=16) | people with non-insulin dependant diabetes | open Parallel groups Sample size: 29/16 Primary endpoint: albuminurea FU duration: 12 months |
| Terano, 1999 | DHA capsules, 6/d (4.3g/d DHA) (n=10) vs. no treatment (n=10) | dementia of CVD | open with blind assessment Parallel groups Sample size: 10/10 Primary endpoint: neurological tests FU duration: 12 months |
| von Schacky, 1999 | concentrated fish oil capsules, 6/d for first 3 mo, 3/d for rest of study (4g/d EPA +DHA + DPA+ a-lin for first 3 mo, then 2g/d) (n=112) vs. placebo (capsules containing fat which replicated the fat composition of the average European diet, 6/d forfirst 3 mo, 3/d for rest of study, opaque soft gelatine capsules identical to fish capsules) (n=111) | people with angiographically proven coronary artery disease | double blind Parallel groups Sample size: 112/111 Primary endpoint: changes in stenosis on angiography> FU duration: 24 months |
